Pharmaceutical Firms Hit Decade High Profits on Tax Waivers and Stable Naira

Nigeria’s pharmaceutical sector has recorded its strongest financial performance in over a decade, driven by government tax waivers and improved currency stability, signalling renewed momentum for the industry.

According to recent reports, pharmaceutical companies listed on the Nigerian Exchange more than doubled their combined profits, rising from ₦6.5 billion in 2024 to ₦14.8 billion in 2025. This marks a significant turnaround for an industry that has long struggled with high input costs, foreign exchange volatility, and margin pressure.

The growth has been largely attributed to the Federal Government’s tax waiver policy on pharmaceutical raw materials, alongside a more stable naira. These measures have helped reduce production costs, improve planning for manufacturers, and protect profit margins despite ongoing economic challenges.

Several leading companies have reported standout performances. Neimeth International Pharmaceuticals moved from a loss position to profitability, while Fidson Healthcare and May & Baker Nigeria posted strong increases in profit, supported by improved margins and growing domestic demand.

Industry leaders have directly linked this recovery to policy intervention. The tax waivers, introduced under broader healthcare reform initiatives, have enabled manufacturers to scale operations, increase capacity utilisation, and compete more effectively within the local market.

However, despite this strong financial performance, challenges remain. Purchasing power across the market is still relatively weak, and affordability of medicines continues to be a concern, highlighting the need for further structural improvements across the value chain.

This evolving landscape presents a clear opportunity for both local and international stakeholders and reinforces the importance of platforms like Pharma West Africa.

As the region’s leading pharmaceutical exhibition, Pharma West Africa connects manufacturers with key importers, distributors, and wholesalers actively seeking cost effective products and reliable supply partnerships. With strong demand across finished formulations, OTC medicines, APIs, and manufacturing solutions, the event provides direct access to one of the fastest growing pharmaceutical markets globally.

Exhibiting at Pharma West Africa allows companies to capitalise on rising market demand while contributing to a more efficient and sustainable supply chain. By enabling direct sourcing relationships and reducing reliance on fragmented procurement channels, the exhibition helps improve pricing efficiency and supports wider access to affordable medicines.

For international manufacturers, it offers a strategic route into West Africa. For local distributors and buyers, it creates opportunities to secure competitive deals and diversify supply sources.

As Nigeria’s pharmaceutical sector continues its upward trajectory, sustained collaboration between government, manufacturers, and distributors will be essential. Platforms like Pharma West Africa will remain central to driving these connections and supporting long term market growth and self sufficiency.